Trial Profile
A multicenter open-label randomized study of BCD-020 (rituximab, CJSC BIOCAD, Russia) efficacy and safety in comparison with MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in monotherapy of CD20-positive indolent non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms BIORIX
- Sponsors Biocad
- 01 Feb 2020 Primary endpoint (Overall response rate [ Time Frame: day 50 (cycle 4) ]) has been met, according to results published in the Hematological Oncology
- 01 Feb 2020 Results published in the Hematological Oncology
- 02 Nov 2017 Status changed from recruiting to completed.